Lipid changes in real-world studies with the two-drug regimen dolutegravir and lamivudine (DTG+3TC) in people with HIV-1: a systematic literature review

被引：0

作者：

Letang, E. ^{[1
]}

Lo, J. ^{[2
]}

Milinkovic, A. ^{[3
]}

Maggiolo, F. ^{[4
]}

di Giambenedetto, S. ^{[5
,6
]}

Mussini, C. ^{[7
,8
]}

Yoruk, I. Ungan ^{[9
]}

Henegar, C. ^{[10
]}

Priest, J. ^{[11
]}

Young, B. ^{[12
]}

Kabra, M. ^{[13
]}

Jones, B. ^{[9
]}

机构：

[1] ViiV Healthcare, Global Med Affairs, Madrid, Spain

[2] Harvard Med Sch, Massachusetts Gen Hosp, Metab Unit, Boston, MA USA

[3] Chelsea & Westminster Hosp, Infect Dis, London, England

[4] Azienda Socio Sanit Terr Papa Giovanni XXIII, Antiviral Therapy Unit, Bergamo, Italy

[5] Fdn Policlin Univ Agostino Gemelli IRCC, Infect Dis, Rome, Italy

[6] Univ Cattolica Sacro Cuore, Rome, Italy

[7] Azienda Osped Univ Policlin, Clin Infect Dis, Infect Dis, Modena, Italy

[8] Univ Modena & Reggio Emilia, Modena, Italy

[9] ViiV Healthcare, Global Med Affairs, Brentford, England

[10] ViiV Healthcare, Epidemiol & Real World Evidence, Durham, NC USA

[11] ViiV Healthcare, Hlth Outcomes, Durham, NC USA

[12] ViiV Healthcare, Global Med Affairs, Durham, NC USA

[13] ViiV Healthcare, Health Outcomes, Brentford, England

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2022年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P165

引用

页码：154 / 156

页数：3

共 42 条

[1] Systematic literature review of real-world experience with the 2-drug regimen dolutegravir plus lamivudine (DTG+3TC) in people with HIV-1 (PWH) aged ≥50 years
Letang, E.
Di Giambenedetto, S.
Monforte, A. d'Arminio
Casado, J.
Cabello-Ubeda, A.
Hocqueloux, L.
Allavena, C.
Barber, T. J.
Kabra, M.
Priest, J.
Clark, A.
Jones, B.
HIV MEDICINE, 2023, 24 : 135 - 137
[2] Real-world experience with the two-drug regimen dolutegravir and lamivudine in women with HIV: a systematic literature review
di Giambenedetto, S.
Walmsley, S.
Grinsztejn, B.
Perez-Elias, M.
Nwokolo, N.
Kabra, M.
Jones, B.
Letang, E.
Kisare, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 51 - 52
[3] HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
Rickesh Patel
Lee Evitt
Ilias Mariolis
Simona Di Giambenedetto
Antonella d’Arminio Monforte
José Casado
Alfonso Cabello Úbeda
Laurent Hocqueloux
Clotilde Allavena
Tristan Barber
Diwakar Jha
Rahul Kumar
Rahul Dinesh Kamath
Tia Vincent
Jean van Wyk
Justin Koteff
Infectious Diseases and Therapy, 2021, 10 : 2051 - 2070
[4] HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
Patel, Rickesh
Evitt, Lee
Mariolis, Ilias
Di Giambenedetto, Simona
Monforte, Antonella D'Arminio
Casado, Jose
Cabello Ubeda, Alfonso
Hocqueloux, Laurent
Allavena, Clotilde
Barber, Tristan
Jha, Diwakar
Kumar, Rahul
Kamath, Rahul Dinesh
Vincent, Tia
van Wyk, Jean
Koteff, Justin
INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2051 - 2070
[5] Effectiveness and tolerability of the two-drug regimen dolutegravir plus lamivudine in people with HIV-1: a systematic literature review of real-world evidence from clinical practice
Letang, Emilio
Priest, Julie
Di Giambenedetto, Simona
Monforte, Antonella d'Arminio
Casado, Jose
Cabello-Ubeda, Alfonso
Hocqueloux, Laurent
Allavena, Clotilde
Barber, Tristan J.
Jha, Diwakar
Kamath, Rahul Dinesh
Sithamparanathan, Myooran
van Wyk, Jean
Evitt, Lee
HIV MEDICINE, 2022, 23 : 37 - 38
[6] Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1579): : 134 - 136
[7] Impact on inflammatory and atherogenesis biomarkers with the two-drug regimen dolutegravir plus lamivudine in treatment-experienced people with HIV-1: a systematic literature review
Llibre, Joseph
Cahn, Pedro E.
Lo, Janet
Barber, Tristan J.
Mussini, Christina
van Welzen, Berend J.
Hernandez, Beatriz
Donovan, Cynthia
Kisare, Michelle
Sithamparanathan, Myooran
van Wyk, Jean
HIV MEDICINE, 2022, 23 : 54 - 55
[8] Real-world effectiveness of Dolutegravir plus Lamivudine (DTG+3TC) in treatment-naive people with HIV-1 (PWH) and low CD4+cell count or high viral load at baseline: A systematic literature review
Letang, E.
Barber, T. J.
Allavena, C.
Hocqueloux, L.
Casado, J.
Di Giambenedetto, S.
Cabello-Ubeda, A.
Monforte, A. d'Arminio
Kabra, M.
Priest, J.
Milinkovic, A.
Jones, B.
HIV MEDICINE, 2023, 24 : 144 - 145
[9] Systematic literature review of real-world experience with the two-drug regimen dolutegravir and lamivudine in people with HIV who would not have met inclusion criteria for the phase III clinical program
Slim, J.
Ward, D.
Schneider, S.
Kabra, M.
Verdier, G.
Jones, B.
Letang, E.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 86 - 88
[10] Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG plus TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
Orkin, C.
Porteiro, N.
Berhe, M.
Dretler, R.
Viciana, P.
Tseng, Y.
Oprea, C.
Johnson, M.
Kulagin, V.
Man, C.
Sievers, J.
Currie, A.
Underwood, M.
Tenorio, A.
Pappa, K.
Wynne, B.
Aboud, M.
Smith, K.
Gartland, M.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21

← 1 2 3 4 5 →